Navigation Links
Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Oral Picoplatin Demonstrating Bioavailability
Date:4/21/2009

- Pharmacologic Data Presented at American Association for Cancer Research's 100th Annual Meeting 2009 -

SOUTH SAN FRANCISCO, Calif. and DENVER, April 21 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today announced the presentation of final data from a Phase 1 clinical study of an oral formulation of picoplatin in patients with solid tumors. Results showed that the bioavailability of oral picoplatin is nearly 100 percent at doses of 50 mg and 100 mg, indicating sufficient bioavailability to support further clinical development.

Picoplatin, the Company's lead product candidate, is a new generation platinum chemotherapy agent in clinical development to treat a variety of solid tumors. It was designed to overcome platinum resistance of the tumor, which remains a medical challenge for oncologists and patients, whose therapeutic options become limited. Poniard is currently evaluating an intravenous formulation of picoplatin in a pivotal Phase 3 trial in patients with small cell lung cancer (SCLC) and in Phase 2 trials in metastatic colorectal cancer (CRC) and metastatic castration-resistant prostate cancer (CRPC).

"The results of the Phase 1 trial demonstrating the oral bioavailability of picoplatin support the continued development of an oral formulation for multiple tumor indications," said Robert De Jager, M.D., chief medical officer of Poniard. "We believe that oral picoplatin may offer opportunities for studies in new indications and in combinations with other chemotherapeutics or with radiation therapy. The administration options for oral picoplatin may provide more convenience to cancer patients and could enable the potential of multiple combination therapies."

The picoplatin data were presented today in a poster ses
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Poniard Pharmaceuticals Announces Upcoming Conference Participation
2. Poniard Pharmaceuticals Reports Second Quarter 2008 Financial Results and Corporate Update
3. Poniard Pharmaceuticals Reports Third Quarter 2008 Financial Results and Corporate Update
4. Poniard Pharmaceuticals Provides 2009 Clinical Data Goals for Picoplatin
5. Poniard Pharmaceuticals Announces Appointment of Greg Weaver as Chief Financial Officer
6. Poniard Pharmaceuticals Receives Going Concern Qualification
7. Poniard Pharmaceuticals to Present at Needham & Companys Cancer Therapeutics: Today & Tomorrow Conference
8. Poniard Pharmaceuticals to Focus Company Resources on Late-Stage Oncology Candidate Picoplatin Through Realignment of Research Organization
9. Poniard Announces Publication of Results of Picoplatin Phase 2 Study in Journal of Clinical Oncology
10. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
11. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2014)... Calif. A single type of cell in the ... of invasive bladder cancer, according to researchers at the ... in mice, is the first to pinpoint the normal ... cancers. It,s also the first to show that most ... just one cell, and explains why many human bladder ...
(Date:4/18/2014)... that turns 160 years of neuroanatomy on its head. ... be essential for the fast transmission of impulses along ... as thought, according to a new work lead by ... (HSCI) and the University,s Department of Stem Cell and ... Harvard,s Department of Molecular and Cellular Biology. , "Myelin ...
(Date:4/18/2014)... Two Simon Fraser University psychologists have made a ... treatment of attention-deficit disorders. , This discovery opens ... may hinder or suppress a specific brain activity ... prevent distraction. , The Journal of Neuroscience ... discovery by John McDonald, an associate professor of ...
(Date:4/17/2014)... chronic inflammation in benign prostate tissue was associated ... association was found even in those with low ... published in Cancer Epidemiology, Biomarkers & Prevention ... Cancer Research. , An analysis of prostate tissue ... arm of the Prostate Cancer Prevention Trial (PCPT) ...
(Date:4/17/2014)... popular vaccine brands for children may not be the ... cost factors when choosing vaccines, driving the market toward ... a new study by University of Illinois researchers. , ... by numerous factors," says Sheldon H. Jacobson, a co-author ... and of mathematics at the U. of I. "In ...
Breaking Medicine News(10 mins):Health News:Stanford scientists identify source of most cases of invasive bladder cancer 2Health News:Stanford scientists identify source of most cases of invasive bladder cancer 3Health News:Stanford scientists identify source of most cases of invasive bladder cancer 4Health News:Stanford scientists identify source of most cases of invasive bladder cancer 5Health News:Finding turns neuroanatomy on its head 2Health News:Finding turns neuroanatomy on its head 3Health News:Scientists discover brain's anti-distraction system 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 3Health News:Study recalculates costs of combination vaccines 2
... of Americans, WASHINGTON, Dec. 5 Many of ... treatment, HHS,Secretary Mike Leavitt said today in marking fulfillment ... community health centers., Health centers deliver primary and ... Charges for health care services at,health centers are set ...
... Dec. 5 One of the greatest fears ... Syndrome), but due to extreme,precautionary measures taken to ... are rising by surprising levels. After the introduction,of ... were reduced,significantly. However, during this same period, children ...
... more than 10 million Americans, Osteoarthritis of the knee ... disability among the elderly. While OA mainly affects ... age. A double-blind, placebo-controlled study published in the journal ... from the bark of the French maritime pine tree, ...
... For patients with dialysis-related anemia, the risk of death ... a period several monthsnot necessarily when they fluctuate over ... Journal of the American Society of Nephrology. , "Our ... mortality, beyond the absolute level of hemoglobin, may not ...
... Certification for Pharmacy Techs, 91% ... Support Standards in Every State, ... the,Pharmacy Technician Certification Board (PTCB) shows that Americans have,strong misperceptions ... in pharmacies. The poll results,released today at the American Society ...
... HILL, N.C., Dec. 5 As companies transform ... with the art of selling while maintaining a ... in facilitating the changeover,the manager/supervisor is one of ... In fact, call center leaders recommend reducing ...
Cached Medicine News:Health News:HHS Marks Expansion of 1200th Health Center, Meeting Key Bush Goal 2Health News:Infant Development Program from EASY Baby Takes On the Sixty-Percent Increase in Developmental Delays in Children 2Health News:Study shows pine bark naturally reduces osteoarthritis knee pain 2Health News:Study shows pine bark naturally reduces osteoarthritis knee pain 3Health News:Study questions impact of hemoglobin variations on mortality in dialysis patients 2Health News:Survey Shows Broad Support Among Americans for Pharmacy Technician Certification 2Health News:Managing the Service-to-Sales Cultural Transformation - Complimentary Excerpt Available from Best Practices 2
(Date:1/15/2014)... , Jan. 15, 2014  A novel wearable injector slightly ... and painless for patients to self-inject prescription drugs in the ... including cancer, blood diseases, autoimmune deficiencies, and genetic disorders.  ... grow to $220B by 2018, according to analysts.   Many of ...
(Date:1/14/2014)... N.J. , Jan. 14, 2014 InformEx, ... and sellers of high-value chemistry, will hold the 30 th ... Miami Beach Convention Center from January 21-24. ... 3,500 attendees from top pharmaceutical, fine chemical and specialty chemical ...
(Date:1/14/2014)... /PRNewswire-iReach/ -- Acumed,s new SLIC Screw System - a ... to place and insert the screw accurately - offers ... ligament) repair or reconstruction as it holds the bones ... http://photos.prnewswire.com/prnh/20140114/MN45636 ) The SLIC Screw ...
Breaking Medicine Technology:Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3
... July 12, 2011 Particle Sciences ... Systems, a leading provider of pre-clinical pharmacokinetic services, ... together to provide their clients with enhanced drug ... the dosage form development scheme.   ...
... Helping Virologists Keep,Up- to- Date ... Elsevier ( http://www.elsevier.com ) has,announced the publication of the first ... in its prestigious Current Opinion,series, publishing six issues a year. ... filtered approach to the ever-expanding wealth of research,published on viruses and ...
Cached Medicine Technology:Particle Sciences and Absorption Systems Form Relationship to Offer their Clients Enhanced Services 2Elsevier Launches Current Opinion in Virology 2
Athroscopic leg holder system....
... Featuring two rapid response roller-pumps, ... maintaining a clear surgical field. Furthermore ... surgeon total control over intra-articular pressure ... system includes foot pedal controls, providing ...
... CD / DVD Burner captures still ... to 50 patient archives allows for ... future retrieval. The unit provides software ... for easy playback and editing. Compatible ...
The Sony DSR20-MD Grade Digital Video Player/Recorder represents a giant leap in digital technology. , ,This equipment is intended to be used by physicians who teach or present medical techniques...
Medicine Products: